{"id":"https://openalex.org/W2962021985","doi":"https://doi.org/10.1039/9781788012898-00073","title":"Auristatin Payloads for Antibody\u2013Drug Conjugates (ADCs)","display_name":"Auristatin Payloads for Antibody\u2013Drug Conjugates (ADCs)","publication_year":2019,"publication_date":"2019-07-11","ids":{"openalex":"https://openalex.org/W2962021985","doi":"https://doi.org/10.1039/9781788012898-00073","mag":"2962021985"},"language":"en","primary_location":{"id":"doi:10.1039/9781788012898-00073","doi":"https://doi.org/10.1039/9781788012898-00073","is_oa":false,"landing_page_url":"https://doi.org/10.1039/9781788012898-00073","pdf_url":null,"source":{"id":"https://openalex.org/S4306463862","display_name":"Royal Society of Chemistry eBooks","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/P4310320556","host_organization_name":"Royal Society of Chemistry","host_organization_lineage":["https://openalex.org/P4310320556"],"host_organization_lineage_names":["Royal Society of Chemistry"],"type":"ebook platform"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cytotoxic Payloads for Antibody \u2013 Drug Conjugates","raw_type":"book-chapter"},"parent_works":[{"id":"https://openalex.org/W4235310102","display_name":"Cytotoxic Payloads for Antibody \u2013 Drug Conjugates","relationship":"volume"}],"lineage":["https://openalex.org/W2962021985","https://openalex.org/W4235310102"],"child_works_count":0,"type":"book-chapter","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5103551444","display_name":"Svetlana O. Doronina","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I99319750","display_name":"Seagen (United States)","ror":"https://ror.org/01vwesc15","country_code":"US","type":"company","lineage":["https://openalex.org/I99319750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Svetlana O. Doronina","raw_affiliation_strings":["Chemistry, Seattle Genetics Inc Bothell Washington 98021 USA Sdoronina@seagen.com"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chemistry, Seattle Genetics Inc Bothell Washington 98021 USA Sdoronina@seagen.com","institution_ids":["https://openalex.org/I99319750"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5089318759","display_name":"Peter D. Senter","orcid":"https://orcid.org/0000-0003-2748-6007","observed_orcids":["https://orcid.org/0000-0003-2748-6007"]},"institutions":[{"id":"https://openalex.org/I99319750","display_name":"Seagen (United States)","ror":"https://ror.org/01vwesc15","country_code":"US","type":"company","lineage":["https://openalex.org/I99319750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Peter D. Senter","raw_affiliation_strings":["Chemistry, Seattle Genetics Inc Bothell Washington 98021 USA Sdoronina@seagen.com"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chemistry, Seattle Genetics Inc Bothell Washington 98021 USA Sdoronina@seagen.com","institution_ids":["https://openalex.org/I99319750"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I99319750"],"apc_list":null,"apc_paid":null,"fwci":1.4064,"has_fulltext":false,"cited_by_count":5,"citation_normalized_percentile":{"value":0.86406844,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":95},"biblio":{"volume":null,"issue":null,"first_page":"73","last_page":"99"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.47999998927116394,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.47999998927116394,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10274","display_name":"Heterocyclic Compound Synthesis and Bioactivity","score":0.17749999463558197,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10911","display_name":"Chemical Synthesis and Analysis","score":0.08139999955892563,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/auristatin","display_name":"auristatin","score":0.9959999918937683},{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.9940000176429749},{"id":"https://openalex.org/keywords/monomethyl-auristatin-e","display_name":"monomethyl auristatin E","score":0.8880000114440918},{"id":"https://openalex.org/keywords/monomethyl-auristatin-f","display_name":"monomethyl auristatin F","score":0.9919999837875366},{"id":"https://openalex.org/keywords/brentuximab-vedotin","display_name":"brentuximab vedotin","score":0.9369999766349792},{"id":"https://openalex.org/keywords/dolastatin-10","display_name":"dolastatin 10","score":0.9390000104904175},{"id":"https://openalex.org/keywords/tubulin-polymerization-inhibitors","display_name":"tubulin polymerization inhibitors","score":0.9539999961853027},{"id":"https://openalex.org/keywords/bystander-effect","display_name":"bystander effect","score":0.574999988079071},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9179999828338623},{"id":"https://openalex.org/keywords/drug-tolerability","display_name":"drug tolerability","score":0.5490000247955322},{"id":"https://openalex.org/keywords/targeted-cancer-therapy","display_name":"targeted cancer therapy","score":0.6859999895095825}],"concepts":[{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.5958455801010132},{"id":"https://openalex.org/C2778191690","wikidata":"https://www.wikidata.org/wiki/Q422324","display_name":"Brentuximab vedotin","level":4,"score":0.5527507066726685},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5313295125961304},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5009720325469971},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.20141470432281494},{"id":"https://openalex.org/C3020616263","wikidata":"https://www.wikidata.org/wiki/Q1216998","display_name":"Tumor cells","level":2,"score":0.1040029525756836},{"id":"https://openalex.org/C70905583","wikidata":"https://www.wikidata.org/wiki/Q3648608","display_name":"CD30","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1039/9781788012898-00073","doi":"https://doi.org/10.1039/9781788012898-00073","is_oa":false,"landing_page_url":"https://doi.org/10.1039/9781788012898-00073","pdf_url":null,"source":{"id":"https://openalex.org/S4306463862","display_name":"Royal Society of Chemistry eBooks","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/P4310320556","host_organization_name":"Royal Society of Chemistry","host_organization_lineage":["https://openalex.org/P4310320556"],"host_organization_lineage_names":["Royal Society of Chemistry"],"type":"ebook platform"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cytotoxic Payloads for Antibody \u2013 Drug Conjugates","raw_type":"book-chapter"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.8371999859809875}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":106,"referenced_works":["https://openalex.org/W181472673","https://openalex.org/W1524815067","https://openalex.org/W1543933515","https://openalex.org/W1557340160","https://openalex.org/W1589293594","https://openalex.org/W1651223554","https://openalex.org/W1968195969","https://openalex.org/W1970522198","https://openalex.org/W1971914635","https://openalex.org/W1975691316","https://openalex.org/W1979824797","https://openalex.org/W1981558181","https://openalex.org/W1989132809","https://openalex.org/W1989891951","https://openalex.org/W1993122592","https://openalex.org/W1994162165","https://openalex.org/W1996937111","https://openalex.org/W1997941840","https://openalex.org/W2000511510","https://openalex.org/W2000753870","https://openalex.org/W2001016990","https://openalex.org/W2002828670","https://openalex.org/W2002913405","https://openalex.org/W2004151829","https://openalex.org/W2004385676","https://openalex.org/W2005307142","https://openalex.org/W2005448579","https://openalex.org/W2006698734","https://openalex.org/W2008447052","https://openalex.org/W2010363872","https://openalex.org/W2011118089","https://openalex.org/W2011739708","https://openalex.org/W2015630200","https://openalex.org/W2023034663","https://openalex.org/W2025096940","https://openalex.org/W2027555013","https://openalex.org/W2028483452","https://openalex.org/W2032158893","https://openalex.org/W2037214204","https://openalex.org/W2038541452","https://openalex.org/W2041914114","https://openalex.org/W2043115278","https://openalex.org/W2044944849","https://openalex.org/W2045612610","https://openalex.org/W2046522614","https://openalex.org/W2047270684","https://openalex.org/W2048944062","https://openalex.org/W2049109311","https://openalex.org/W2049896547","https://openalex.org/W2053755420","https://openalex.org/W2053800409","https://openalex.org/W2058042279","https://openalex.org/W2059539849","https://openalex.org/W2059541007","https://openalex.org/W2068375978","https://openalex.org/W2073429992","https://openalex.org/W2087516193","https://openalex.org/W2090057677","https://openalex.org/W2093580676","https://openalex.org/W2094288422","https://openalex.org/W2094927656","https://openalex.org/W2097995306","https://openalex.org/W2100106580","https://openalex.org/W2107006180","https://openalex.org/W2109697114","https://openalex.org/W2118102300","https://openalex.org/W2120780947","https://openalex.org/W2124560587","https://openalex.org/W2126183505","https://openalex.org/W2136101268","https://openalex.org/W2138352319","https://openalex.org/W2139891818","https://openalex.org/W2148127139","https://openalex.org/W2152622505","https://openalex.org/W2155256323","https://openalex.org/W2171368669","https://openalex.org/W2171908076","https://openalex.org/W2179836657","https://openalex.org/W2183643866","https://openalex.org/W2231446168","https://openalex.org/W2290649187","https://openalex.org/W2301478649","https://openalex.org/W2316159879","https://openalex.org/W2325436294","https://openalex.org/W2327452962","https://openalex.org/W2341089209","https://openalex.org/W2417431203","https://openalex.org/W2487451536","https://openalex.org/W2500482667","https://openalex.org/W2507779661","https://openalex.org/W2510341570","https://openalex.org/W2515272500","https://openalex.org/W2516326580","https://openalex.org/W2551326875","https://openalex.org/W2565596567","https://openalex.org/W2592467398","https://openalex.org/W2597720565","https://openalex.org/W2600794933","https://openalex.org/W2623658063","https://openalex.org/W2729831668","https://openalex.org/W2767025650","https://openalex.org/W2768551101","https://openalex.org/W2950788130","https://openalex.org/W4230483407","https://openalex.org/W4234505122","https://openalex.org/W4318443909"],"related_works":["https://openalex.org/W2148127139","https://openalex.org/W2886511670","https://openalex.org/W3093094945","https://openalex.org/W4393075747","https://openalex.org/W4393085166","https://openalex.org/W4411554950","https://openalex.org/W4207040896","https://openalex.org/W1901302412","https://openalex.org/W3029419287","https://openalex.org/W4236431147"],"abstract_inverted_index":{"The":[0,89,181],"auristatins":[1,93,115,182],"are":[2,58,146],"a":[3,18,25],"synthetic-peptide-based":[4],"drug":[5,48,56,163,195],"class":[6,57,196],"that":[7,45,198],"inhibit":[8],"tubulin":[9],"polymerization":[10],"and":[11,35,70,110,129,157,179,190],"can":[12],"display":[13],"exceptionally":[14],"high":[15],"potency":[16],"on":[17,122],"broad":[19],"array":[20],"of":[21,28,37,63,72,91,100,112,135,150,166],"cancer":[22],"cells.":[23,52],"Consequently,":[24],"tremendous":[26],"amount":[27],"research":[29],"has":[30],"been":[31,138],"focused":[32],"the":[33,47,55,79,83,92,98,101,108,123,147,151,158,162,194],"design":[34,109],"utilization":[36],"auristatin":[38,75,131],"family":[39,126],"members":[40],"within":[41,54,60,186,193],"antibody\u2013drug":[42],"conjugates":[43],"(ADCs)":[44],"deliver":[46],"to":[49,107,160,173,202],"antigen-positive":[50],"tumour":[51],"Molecules":[53],"present":[59],"nearly":[61],"half":[62],"all":[64],"ADCs":[65],"currently":[66],"in":[67,82,141],"clinical":[68,142],"use,":[69],"one":[71],"them,":[73],"monomethyl":[74,130],"E":[76],"(MMAE)":[77],"is":[78,94,120],"active":[80],"payload":[81],"clinically-approved":[84],"drug,":[85],"brentuximab":[86],"vedotin":[87],"(ADCETRIS\u2122).":[88],"history":[90],"described,":[95],"starting":[96],"from":[97],"discovery":[99],"parental":[102],"natural":[103],"product":[104],"dolastatin":[105],"10":[106],"validation":[111],"novel":[113],"synthetic":[114,155],"for":[116,164],"targeted":[117],"delivery.":[118],"Focus":[119],"placed":[121],"most":[124],"well-known":[125],"members,":[127],"MMAE":[128],"F":[132],"(MMAF),":[133],"both":[134],"which":[136],"have":[137,183],"extensively":[139],"investigated":[140],"settings.":[143],"Also":[144],"discussed":[145],"unique":[148],"features":[149],"auristatins,":[152],"such":[153],"as":[154],"accessibility":[156],"ability":[159],"modify":[161],"control":[165],"potency,":[167],"cell":[168],"permeability,":[169],"bystander":[170],"effects,":[171],"susceptibility":[172],"multidrug":[174],"resistance":[175],"efflux,":[176],"pharmacokinetics,":[177],"activity":[178],"tolerability.":[180],"featured":[184],"prominently":[185],"modern":[187],"ADC":[188],"research,":[189],"new":[191],"developments":[192],"indicate":[197],"they":[199],"will":[200],"continue":[201],"do":[203],"so.":[204]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":1}],"updated_date":"2026-11-14T11:04:58.165337","created_date":"2019-07-23T00:00:00"}